Bicara Therapeutics Inc. (NASDAQ:BCAX – Get Free Report) major shareholder James E. Flynn purchased 70,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 17th. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $1,260,000.00. Following the transaction, the insider now owns 897,587 shares in the company, valued at approximately $16,156,566. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Bicara Therapeutics Price Performance
Shares of BCAX opened at $25.73 on Thursday. Bicara Therapeutics Inc. has a 52 week low of $21.05 and a 52 week high of $27.94.
Bicara Therapeutics Company Profile
Featured Articles
- Five stocks we like better than Bicara Therapeutics
- What is the Dow Jones Industrial Average (DJIA)?
- How Much Can You Make in Stocks in One Month?
- Retail Stocks Investing, Explained
- This Is the Top Large-Cap Stock Insiders Are Buying
- Why Invest in 5G? How to Invest in 5G Stocks
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for Bicara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.